INT42994

Context Info Confidence 0.35 First Reported 1982 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 21 Total Number 25 Disease Relevance 14.17 Pain Relevance 4.00

Anatomy Link Frequency lymphocytes 1 neurons 1 brain 1 platelet 1 GBM 1 BDNF-AS (Homo sapiens)

Pain Link Frequency Relevance Heat drug abuse 4 99.28 Enkephalin 26 98.72 Arthritis 114 98.36 pain flank 1 97.56 rheumatoid arthritis 184 97.44 corticosteroid 14 97.04 Pain 11 93.84 Central nervous system 2 91.80 addiction 1 90.28 opiate 1 89.88

Disease Link Frequency Relevance Heat Renal Disease 246 100.00 Hepatitis C Virus Infection 121 100.00 Acquired Immune Deficiency Syndrome Or Hiv Infection 16 100.00 Intravenous Substance Abuse 4 99.76 Disease 291 99.52 Systemic Lupus Erythematosus 635 99.20 Exanthema 1 98.76 Arthritis 108 98.36 Flank Pain 1 97.56 Rheumatoid Arthritis 184 97.44

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Anti-Ro is associated closely with a photosensitive rash and with subacute lupus.

Anti-Ro Binding (associated) of associated with exanthema and systemic lupus erythematosus

1) Confidence 0.35 Published 2006 Journal Clin. Dermatol. Section Abstract Doc Link 16966017 Disease Relevance 0.98 Pain Relevance 0.24

Anti-HCV status was independently associated with duration of drug use of over 10 years, injecting as a route of drug administration, and hepatitis B virus (HBV) and human immunodeficiency virus (HIV) seropositivity.

Anti-HCV Binding (associated) of associated with acquired immune deficiency syndrome or hiv infection, hepatitis b virus infection, hepatitis c virus infection and hepatitis

2) Confidence 0.30 Published 2003 Journal J. Viral Hepat. Section Abstract Doc Link 12969192 Disease Relevance 1.38 Pain Relevance 0.14

In our cohort we did not find a substantial association between anti-MCV levels and disease activity.

anti-MCV Neg (not) Binding (association) of associated with disease

3) Confidence 0.05 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2374444 Disease Relevance 0.54 Pain Relevance 0.09

The present study focuses on the association between anti-MCV levels and DAS28 in patients with early arthritis over 2 years of follow up.

anti-MCV Binding (association) of associated with arthritis

4) Confidence 0.05 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2374444 Disease Relevance 1.13 Pain Relevance 0.42

GEE analysis revealed a significant association between DAS28 and anti-MCV during 2 years of follow up, although the association was very low.

anti-MCV Binding (association) of

5) Confidence 0.04 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2374444 Disease Relevance 0.22 Pain Relevance 0.11

Two other anti-LAM1 antibodies, anti-LAM1-3 and anti-LAM1-5 stay antigen-bound at the same time.

anti-LAM1 Binding (antigen-bound) of

6) Confidence 0.04 Published 1993 Journal Mol. Immunol. Section Abstract Doc Link 7505884 Disease Relevance 0.09 Pain Relevance 0

Brief treatment of human peripheral blood lymphocytes with the potential anti-HIV compound aurintricarboxylic acid (ATA) prompts the selective release of already bound L-selectin-specific anti-Leu8 and anti-LAM1-1 antibodies from the cells.

anti-LAM1 Binding (bound) of in lymphocytes associated with acquired immune deficiency syndrome or hiv infection

7) Confidence 0.04 Published 1993 Journal Mol. Immunol. Section Abstract Doc Link 7505884 Disease Relevance 0.10 Pain Relevance 0

The peptides are produced after stimulation with the mitogenic monoclonal antibodies anti-CD2.1/2.2 and anti-CD28.

anti-CD28 Binding (stimulation) of

8) Confidence 0.03 Published 1998 Journal J. Neuroimmunol. Section Abstract Doc Link 9600708 Disease Relevance 0 Pain Relevance 0.84

In an in vitro assay system, immobilized epratuzumab crosslinked with anti-IgG had different effects, depending on the cell type studied.

anti-IgG Binding (crosslinked) of

9) Confidence 0.02 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376077 Disease Relevance 0.52 Pain Relevance 0

Immunoglobulin G anti-dsDNA autoantibodies were associated with positivity for ANA, and remained positive until the end of the study, including three of four positive patients who discontinued the treatment.

anti-dsDNA Binding (associated) of

10) Confidence 0.02 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526573 Disease Relevance 0.30 Pain Relevance 0.46

Factors independently associated with positive anti-HBc were IVDA, foreign country of birth, non-white ethnicity and high age.

anti-HBc Binding (associated) of

11) Confidence 0.02 Published 2007 Journal BMC Gastroenterol Section Body Doc Link PMC1797181 Disease Relevance 1.58 Pain Relevance 0.30

Factors independently associated with positive anti-HBc were intravenous drug abuse (OR 18.3; 11.3 to 29.7), foreign country of birth (3.4; 2.6 to 4.4), non-white ethnicity (2.7; 1.9 to 3.8) and age ?

anti-HBc Binding (associated) of associated with intravenous substance abuse and drug abuse

12) Confidence 0.02 Published 2007 Journal BMC Gastroenterol Section Abstract Doc Link PMC1797181 Disease Relevance 1.36 Pain Relevance 0.20

The prerequisite for binding of anti-DNA antibodies is the recognition of either a phosphosugar backbone of dsDNA (for anti dsDNA autoantibodies) or a thymidine pentamer in ssDNA (for antiss-DNA autoantibodies) while the prerequisite for hydrolysis is binding itself.

anti-DNA Binding (binding) of

13) Confidence 0.02 Published 2010 Journal Autoimmune Diseases Section Body Doc Link PMC2989704 Disease Relevance 0.27 Pain Relevance 0

Most of the authors used DNA-cellulose purification based upon the technique pioneered by Moss et al. [3] wherein the DNA bound either anti-ssDNA or anti-dsDNA or both directly from sera.

anti-dsDNA Binding (bound) of

14) Confidence 0.02 Published 2010 Journal Autoimmune Diseases Section Body Doc Link PMC2989704 Disease Relevance 0 Pain Relevance 0

Tanner et al. in 2001 illustrated the specific binding of anti-DNA antibodies to thymidine polymers via arginine groups using X-ray analysis.

anti-DNA Binding (binding) of

15) Confidence 0.02 Published 2010 Journal Autoimmune Diseases Section Body Doc Link PMC2989704 Disease Relevance 0 Pain Relevance 0

To our knowledge, our lab was the first to develop a specific and simple method for isolating and purifying human anti-DNA (IgG) antibodies from the SLE patients' serum, based on the specific binding of anti-DNA antibodies to thymine polymers (anti-DNA antibody base specificity is dT ?

anti-DNA Binding (binding) of associated with systemic lupus erythematosus

16) Confidence 0.02 Published 2010 Journal Autoimmune Diseases Section Body Doc Link PMC2989704 Disease Relevance 0.26 Pain Relevance 0

The methods created and applied in the past were mainly done to detect the anti-DNA structural and functional characteristics (e.g., substrate binding, hydrolytic, and cytotoxic activity).

anti-DNA Binding (binding) of

17) Confidence 0.01 Published 2010 Journal Autoimmune Diseases Section Body Doc Link PMC2989704 Disease Relevance 0.23 Pain Relevance 0

A greater proportion of anti-dsDNA IgG-binding antibodies purified from patients with active lupus nephritis binds to ?

anti-dsDNA Binding (binds) of associated with renal disease

18) Confidence 0.01 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2857808 Disease Relevance 0.78 Pain Relevance 0

At multivariate analysis, a combination of anti-C1q, C3, and C4 provided the best performance for predicting renal flares.

anti-C1q Binding (combination) of

19) Confidence 0.01 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2857808 Disease Relevance 0.98 Pain Relevance 0

Since platelet aggregation has been demonstrated to be mediated exclusively by the binding of plasma fibrinogen to the activated GP IIb/IIIa, anti-GP IIb/IIIa agents, which can completely inhibit platelet aggregation, were expected to become among the most potent of antithrombotic agents.

anti-GP Binding (become) of in platelet

20) Confidence 0.01 Published 2004 Journal Curr Vasc Pharmacol Section Abstract Doc Link 15320830 Disease Relevance 0.43 Pain Relevance 0.16

General Comments

This test has worked.